Could two new drugs boost chemo success in HER2-Low breast cancer?
NCT ID NCT07317778
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether adding the drugs SHR-A1811 and/or adebrelimab to standard chemotherapy can improve outcomes for people with HR-positive, HER2-low early-stage breast cancer. About 249 participants will receive either chemo alone, chemo plus adebrelimab, or a sequence of SHR-A1811, adebrelimab, and chemo before surgery. The main goal is to see if these combinations lead to a higher rate of complete tumor disappearance (pathological complete response) at the time of surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-A1811 (Trastuzumab Rezetecan) and Adebrelimab (PD-L1 inhibitor)
- What this could lead to
- If successful, this could lead to a more effective neoadjuvant treatment for HR+/HER2-low early breast cancer, potentially increasing the chance of a complete response before surgery.
- What could go wrong
- This is an early phase II trial with a moderate size (249 participants). The combination may not improve outcomes over standard chemo and could have added side effects. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER EARLY STAGE BREAST CANCER (STAGE 1-3) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Center/Cancer hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, 100021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Exercise during chemo: a new weapon to preserve strength?
- Could a smartphone program ease Chemo's emotional toll?
- Could fewer heart tests be safer for breast cancer patients?
- New drug cocktail shows promise for Hard-to-Treat breast cancer before surgery
- New study aims to predict who will respond to breast cancer therapy
- Blood test could revolutionize breast cancer monitoring